NOMAD TECH(08645.HK)附屬斥8,000元收購資訊科技服務業務
NOMAD TECH(08645.HK)公佈,於昨日(26日),公司全資附屬Goodway Max Limited以代價8,000元向高玉森收購中國米蟲科技控股的全部股權。
中國米蟲持有米蟲深圳的全部股本。中國米蟲及米蟲深圳爲提供資訊科技服務、雲端安全、雲端即服務、網絡安全及互聯網安全管理業務的公司。
公司指,透過收購事項,公司已在香港及內地建立業務發展及營運基地。因此,公司將能拓展其在香港及內地市場提供網絡支援服務及網絡連接服務的現有業務。董事會認爲長遠而言,收購將可拓寬其收入來源,提升集團的財務表現及股東回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.